Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
- PMID: 31231925
- PMCID: PMC6771798
- DOI: 10.1002/da.22895
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Abstract
Anxiety Disorders often show a chronic course, even when treated with one of the various effective treatments available. Lack of treatment effect could be due to Treatment Resistance (TR). Consensus on a definition for TR Anxiety Disorders (TR-AD) is highly needed as currently many different operationalizations are in use. Therefore, generalizability in current TR-AD research is suboptimal, hampering improvement of clinical care. The objective of this review is to evaluate the currently used definitions of TR-AD by performing a systematic review of available literature. Out of a total of n = 13 042, 62 studies that operationalized TR-AD were included. The current review confirms a lack of consensus on TR-AD criteria. In 62.9% of the definitions, TR was deemed present after the first treatment failure. Most studies (93.0%) required pharmacological treatment failures, whereas few (29.0%) required psychological treatment failures. However, criteria for what constitutes "treatment failure" were not provided in the majority of studies (58.1%). Definitions for minimal treatment duration ranged from at least 4 weeks to at least 6 months. Almost half of the TR-AD definitions (46.8%) required elevated anxiety severity levels in TR-AD. After synthesis of the results, the consensus definition considers TR-AD present after both at least one first-line pharmacological and one psychological treatment failure, provided for an adequate duration (at least 8 weeks) with anxiety severity remaining above a specified threshold. This definition could contribute to improving course prediction and identifying more targeted treatment options for the highly burdened subgroup of TR-AD patients.
Keywords: CBT/ cognitive behavioral therapy; anxiety disorders; assessment/diagnosis; pharmacotherapy; treatment resistance.
© 2019 The Authors. Depression and Anxiety Published by Wiley Periodicals, Inc.
Figures
References
-
- American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (fifth). Washington, DC: American Psychiatric Association.
-
- Bakish, D. , Hooper, C. L. , West, D. L. , Miller, C. , Blanchard, A. , & Bashir, F. (1995). Moclobemide and specific serotonin re‐uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology: Clinical and Experimental, 10(2), 105–109. 10.1002/hup.470100205 - DOI
-
- Baldwin, D. , Stein, M. B. , & Hermann, R. (2016). Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. November 22, 2016, Retrieved from. https://www.uptodate.com/contents/generalized‐anxiety‐disorder‐in‐adults...
